

2645-5956

*Dopamine
Receptor
Agonists*

Edited by

*GEORGE POSTE and
STANLEY T. CROOKE*

*Smith Kline & French Laboratories
Philadelphia, Pennsylvania*

PLENUM PRESS · NEW YORK AND LONDON

Contents

I. DOPAMINE RECEPTORS

Chapter 1

Pharmacological and Biochemical Characterization of Two Categories of Dopamine Receptor

John W. Keabian

1. Introduction	3
1.1. Classification of Receptors: General Comments	4
1.2. Dopamine and Dopamine Receptors: History	5
2. The D-1 Receptor	7
3. The Intermediate Lobe of the Rat Pituitary Gland: A Model of the D-2 Receptor	7
3.1. The IL β Adrenoceptor	8
3.2. The IL D-2 Receptor	9
4. Ramifications of the Two-Dopamine-Receptor Hypothesis	13
4.1. Drugs Discriminating between the D-1 and the D-2 Receptors	13
4.2. The "DA Receptors" versus the "D Receptors"	16
4.3. Is the Prejunctional Dopamine Receptor a Distinct Entity?	17
5. Conclusions	17
References	18

Chapter 2

Radioligand Binding Studies of Agonist Interactions with Dopamine Receptors

I. Creese, S. E. Leff, D. R. Sibley, and M. W. Hamblin

1. Direct Receptor Characterization: Radioligand Binding Studies	23
2. The Pituitary D-2 Receptor	26
2.1. Binding Studies	26
2.2. Ergot Interactions with Pituitary D-2 Dopamine Receptors	35
3. Dopamine Receptors in the CNS	45
3.1. [³ H]-Butyrophenone Binding: Labeling D-2 Receptors	46
3.2. Solubilization and Isolation of D-2 Receptors	47
3.3. [³ H]-Thioxanthene Binding: Labeling D-1 Receptors ..	48
3.4. [³ H]-Agonist Binding Sites	49
4. Concluding Comments	54
References	57

Chapter 3

Quantitative Assay of Dopamine Receptor Subtypes

Rita M. Huff and Perry B. Molinoff

1. Introduction	65
2. Interactions of Agonists with Dopamine Receptors	67
3. Assay of D-2A and D-2B Receptors	70
4. Serotonin Receptors in the Striatum	75
5. D-1 Receptors	77
6. Conclusions	81
References	84

Chapter 4

Structure-Activity Relationships of Dopamine Receptor Agonists

Carl Kaiser

1. Introduction	87
-----------------------	----

2. Derivation and General Classification of Dopamine Receptor Agonists	88
2.1. Acyclic Dopamine Derivatives	89
2.2. Dopamine Analogues Incorporating the Side Chain in a Cyclic System	91
2.3. Miscellaneous Dopamine Receptor Agonists	98
3. Structure–Activity Considerations	103
3.1. Dopaminergic Pharmacophore	103
3.2. Conformational Considerations	106
3.3. Lipophilicity	116
3.4. Enantioselectivity	116
4. Summary of Structural Requirements for Dopamine Receptor Agonist Activity	118
5. Conceptual Models of Dopamine Receptor(s)	119
6. Prospectives for Rational Derivation of New Dopamine Receptor Agonists	121
References	122

Chapter 5

Peripheral Dopamine Receptors

M. G. Bogaert, W. A. Buylaert, R. A. Lefebvre, and J. L. Willems

1. Introduction	139
2. Dopamine Receptors in the Cardiovascular System	140
2.1. Differences between Pre- and Postsynaptic Receptors	140
2.2. Comparison of Peripheral with Central Dopamine Receptors	144
3. Dopamine Receptors Mediating Ganglionic Inhibition	145
4. Peripheral Dopamine Receptors in the Gastrointestinal System	146
4.1. Gastrointestinal Secretion	147
4.2. Gastrointestinal Motility	147
5. Conclusion	151
References	151

Chapter 6

Pharmacological Significance of Pre- and Postsynaptic Dopamine Receptors

Salomon Z. Langer and Sonia Arbilla

1. Introduction	157
---------------------------	-----

2. Dopamine Receptors Mediating the Inhibition of Peripheral Noradrenergic Neurotransmission	158
3. Postsynaptic Dopamine Receptors in Vascular Smooth Muscle	161
4. Inhibition of Central Noradrenergic Neurotransmission by Dopamine Receptor Agonists	164
5. Presynaptic Dopamine Autoreceptors and the Modulation of the Release of Dopamine in the Central Nervous System . . .	165
6. Dopamine Receptors Modulating the Release of Acetylcholine from the Striatum	166
7. Inhibition by <i>d</i> -Amphetamine of the Electrically Evoked Release of [³ H]-Acetylcholine from the Rat Striatum	167
8. Dopamine Receptors Involved in the Inhibition of the Release of Other Neurotransmitters	170
9. Dopamine Receptor Subtypes: Pharmacological Characterization of Presynaptic and Postsynaptic Dopamine Receptors	170
10. Conclusions	172
References	173

II. DOPAMINE AGONIST FUNCTION AND PHARMACOLOGY

Chapter 7

Dopamine: An Endogenous Peripheral Neurotransmitter

N. H. Neff, M. Hadjiconstantinou, and Z. Lackovic

1. Introduction	179
2. Peripheral Nerves where Dopamine is Postulated to Function as a Neurotransmitter	180
2.1. Sympathetic Ganglion Small Intensely Fluorescent Cells	180
2.2. Dopamine-Containing Peripheral Nerves	183
2.3. Measurement of Dopamine and Its Metabolite in Peripheral Nerves	184
3. Peripheral Tissues and Organs where There Is Evidence for Dopaminergic Innervation	185
3.1. The Gastrointestinal Tract	185

3.2. The Reproductive System	186
3.3. The Endocrine and Exocrine Glands	186
3.4. The Kidney and Renal Vessels	187
3.5. The Cardiovascular System	188
4. Conclusions	190
References	190

Chapter 8

Vascular Dopamine and Dopamine Receptor Agonists

Barry A. Berkowitz, Robert Erickson, Bodgan Zabko-Potavpovich, and Eliot H. Ohlstein

1. Introduction	195
2. Can Endogeneous Dopamine Concentrations Be Regulated for Therapeutic Advantage?	195
3. Characterization of Dopamine Receptor Agonists in the Vasculature	197
3.1. <i>In Vivo</i>	197
3.2. <i>In Vitro</i>	198
4. Isolated Rabbit Blood Vessels as Model Systems for the Study of Vascular Dopamine and Dopamine Receptor Agonists: SK&F 82526	201
5. What is the Location of Vascular Dopamine Receptors?	204
6. Are Dopamine Vascular Receptors Suberved by a Dopaminergic Innervation?	205
References	206

Chapter 9

Dopamine Receptor Agonists and Hypertension

Mustafa F. Lokhandwala and Richard J. Barrett

1. Introduction	209
2. Cardiovascular Actions of Pergolide in Neurogenic Hypertensive Dogs	210

3. Presynaptic Dopaminergic Inhibition of Sympathetic Nerve Function by Pergolide	213
4. Centrally Mediated Cardiovascular Actions of Pergolide	215
5. Involvement of Central Nervous System Dopamine Receptors in the Antihypertensive Action of Pergolide	217
6. Cardiovascular Dopamine Receptors and Antihypertensive Drug Action	219
7. Summary	220
References	221

III. CRITICAL CONCEPTS OF PHYSIOLOGICAL AND MOLECULAR MECHANISMS OF CARDIOVASCULAR AND RENAL FUNCTION

Chapter 10

Role of Inflammatory Cells in Metabolic and Cellular Alterations Underlying the Exaggerated Renal Prostaglandin and Thromboxane Synthesis in Ureter Obstruction

Philip Needleman

1. Exaggerated Arachidonate Metabolism in the Perfused Hydronephrotic Kidney	227
2. Sites of Enhanced Prostaglandin Synthesis	228
2.1. Qualitative Changes in Renal Arachidonate Metabolism	228
2.2. Kinetic Comparison of Renal Microsomal Arachidonate Metabolism in Normal and Ureter-Obstructed Rabbit Kidneys	229
2.3. Slice Experiments for Localization of the Metabolic Changes in the HNK	230
2.4. Quantitative Comparison of PGE ₂ and TxB ₂ Released from the Isolated Intact Perfused Hydronephrotic Rabbit Kidney	230
3. Role of Mononuclear Cells in the Exaggerated Arachidonate Metabolism in Renal Injury	231
References	233

Chapter 11

The Kidney and Hypertension

Arthur C. Guyton, R. Davis Manning, Thomas E. Lohmeier, and John E. Hall

1. Introduction	237
1.1. Nervous Feedback Mechanisms	238
1.2. The Intermediate-Term Pressure Control Mechanisms ..	239
1.3. The Long-Term Mechanisms	240
2. The Renal Blood Volume-Pressure Control System	240
2.1. Basic Mechanism and Infinite Gain Characteristic	240
2.2. The Two Determinants of the Long-Term Arterial Pressure Level—The Significance of the Infinite Gain Characteristic	242
2.3. Volume-Loading Hypertension and the Role of “Autoregulation” to Increase Total Peripheral Resistance	242
3. The Noncauses of Hypertension: Increased Total Peripheral Resistance, Increased Heart Strength, and Decreased Vascular Capacitance	246
4. The Chronic Salt-Loading Renal Function Curve	248
4.1. Role of the Renin-Angiotensin System to Shift the Acute Renal Function Curve and to Steepen the Chronic Salt- Loading Renal Function Curve	250
4.2. Other Factors That Steepen the Chronic Salt-Loading Renal Function Curve	251
4.3. Use of the Chronic Salt-Loading Renal Function Curve to Analyze Different Types of Hypertension	252
5. Role of the Kidneys in Essential Hypertension	254
6. Summary	256
References	256

Chapter 12

Molecular Mechanisms of Vasodilatation

Louis J. Ignarro, Carl A. Gruetter, Albert L. Hyman, and Philip J. Kadowitz

1. Introduction	259
-----------------------	-----

2. Vasodilator Actions of Nitric Oxide and Nitrosoamines	261
2.1. Nitric Oxide	261
2.2. Nitrosoamines	263
2.3. Conclusions	264
3. Nitric Oxide as an Intermediate of the Nitrogen-Oxide- Containing Vasodilators	264
3.1. Nitrosoamines and Sodium Nitroprusside	265
3.2. Inorganic and Organic Nitrites	265
3.3. Organic Nitrates	266
3.4. Hydroxylamine and Sodium Azide	266
3.5. Conclusions	266
4. Relationship between Cyclic GMP Formation and Vascular Smooth Muscle Relaxation	267
4.1. Cyclic GMP as a Relaxant	267
4.2. Activation of Guanylate Cyclase	267
4.3. Inhibition of Cyclic GMP Phosphodiesterase	268
4.4. Vascular Cyclic GMP Accumulation	269
4.5. Cyclic GMP as Second Messenger	270
5. Antagonism by Methylene Blue of Relaxation by Nitrogen- Oxide-Containing Vasodilators	272
5.1. Specificity and Mechanisms of Antagonism	272
5.2. Receptors	274
6. S-Nitrosothiols as Active Intermediates of the Nitrogen- Oxide-Containing Vasodilators	274
6.1. Thiol Enhancement of Guanylate Cyclase Activation	275
6.2. Cysteine Requirement for Guanylate Cyclase Activation by Organic Nitrates	275
6.3. S-Nitrosothiol Formation from Nitrogen-Oxide- Containing Vasodilators	275
6.4. Potent Vasodilator Action of S-Nitrosothiols	276
6.5. S-Nitrosothiols Stimulate Vascular Cyclic GMP Formation	277
6.6. Conclusions	278
7. Mechanism of the Vasodilator Action of Acetylcholine	279
7.1. Role of Vascular Endothelial Cells	279
7.2. Antagonism by Atropine, Quinacrine, and Methylene Blue	279
7.3. Elevation of Cyclic GMP Levels	280
7.4. Conclusions	280
8. Molecular Mechanisms of Cyclic GMP Accumulation and Vasodilatation	280

8.1. Vascular Tolerance to Organic Nitrates	282
8.2. Physiological Role of Cyclic GMP in the Control of Vascular Tone	282
References	284

IV. CLINICAL APPLICATIONS

Chapter 13

The Relationship of Receptor Actions of Dopamine Agonists to Their Clinical Effects

Leon I. Goldberg

1. Introduction	291
2. Shock	293
3. Congestive Heart Failure	293
3.1. Dopamine	293
3.2. Levodopa	293
3.3. Ibopamine	294
3.4. Propylbutyldopamine	294
3.5. Bromocriptine	295
4. Hypertension	295
5. Renal Failure	297
6. Endocrine Response	297
7. Summary	298
References	298

Chapter 14

Hemodynamic Factors Involved in the Regulation of Sodium Balance

Jay H. Stein

1. Introduction	303
2. Renal Handling of Sodium	303
3. Factors Regulating Renal Sodium Handling	306

3.1. Glomerular Filtration Rate	306
3.2. Hormonal Factors	307
3.3. Sympathetic Activity	308
4. Hemodynamic Factors	308
5. Medullary Blood Flow	311
6. Redistribution of Blood Flow and/or Filtrate	312
7. Effect of Dopamine on Urinary Sodium Excretion	314
References	314

Chapter 15

Dopaminergic Mechanisms in the Control of Aldosterone Secretion: A Critical Appraisal

Robert M. Carey

1. Introduction	317
2. Dopamine Antagonists	318
2.1. Metoclopramide	318
2.2. Sulpiride	320
2.3. Chlorpromazine	321
2.4. Domperidone	321
3. Dopamine Agonists	321
3.1. Dopamine	321
3.2. Bromocriptine	323
3.3. SKF 82526-J	324
4. Site of Dopaminergic Inhibition of Aldosterone Secretion	324
5. Physiological Significance of Dopamine in the Control of Aldosterone Secretion	326
6. Summary and Conclusions	327
References	327

Chapter 16

Dopamine Agonists/Antagonists in the Treatment of Gastrointestinal Diseases

Herbert S. Ormsbee III

1. Introduction	333
-----------------	-----

2. Actions of Dopamine on the Gastrointestinal Tract	334
2.1. Esophagus	334
2.2. Stomach	334
2.3. Small Intestine and Colon	336
2.4. Gastrointestinal Circulation	337
2.5. Pancreas	338
3. Evidence for Dopamine Receptors in the Gastrointestinal Tract	338
4. Evidence against Dopamine Receptors in the Gastrointestinal Tract	340
5. Pharmacology of Dopamine Antagonists in the Gastrointestinal Tract	341
5.1. Pharmacology of Metoclopramide	342
5.2. Pharmacology of Domperidone	344
5.3. Newer Dopamine Antagonists	346
6. Therapeutic Implications of Dopamine Agonists and Antagonists—Present and Future	347
6.1. Dopamine Agonists	347
6.2. Dopamine Antagonists	348
References	349

Chapter 17

The Use of Dopamine Agonists and Antagonists in Neurology

Harold L. Klawans, Christopher G. Goetz, and Caroline M. Tanner

1. Introduction	355
2. Agonists	355
2.1. Bromocriptine	357
2.2. Lergotrile	358
2.3. Pergolide	359
3. Antagonists	362
References	369
<i>Index</i>	373